Amgen 2006 Annual Report Download - page 12

Download and view the complete annual report

Please find page 12 of the 2006 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 38

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38

Amgen 2006 Annual Report 10
“We are working to realize the full
potential of Vectibix™as a cancer
therapeutic. Our mandate is to
deliver the evidence.”
“Vectibix™ gives some patients
suffering from metastatic
colorectal cancer a new option.”
Rafael, executive director, Global Development, Vectibix™ (panitumumab)
Rafael oversees worldwide clinical trials of panitumumab. He came to
Amgen after several years as an academic oncologist and clinical trial
investigator for the product. He explains, “As a practicing oncologist,
your decisions impact one patient at a time. Working in clinical
development for a company like Amgen, your contributions can help
change medical practice and impact millions of lives.”
Thomas H. Cartwright, M.D., Ocala Oncology Center
Dr. Cartwright has practiced medical oncology for 25 years. He is
currently associate chair of the Gastrointestinal Research Committee
for US Oncology, a national group dedicated to advancing clinical trials
to find new cancer treatments. Nurse Practitioner Renee Genther
supports Dr. Cartwright at the Ocala Oncology Center in Ocala, Florida.